BioLineRx Ltd. has revealed that stage IV pancreatic ductal adenocarcinoma (PDAC) patients treated with the triple combination of motixafortide (BL-8040), KEYTRUDA® (pembrolizumab) and chemotherapy in its COMBAT/KEYNOTE-202 clinical study had a meaningful improvement in their overall and progression free survival.
The triple combination study arm enrolled a total of 43 patients initially diagnosed with unresectable stage IV metastatic PDAC, who had progressed following first-line gemcitabine-based therapy. Read more . . .